Use of CDK9 and BRD4 inhibitors to inhibit inflammation
View Patent ↗Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
1. A method of treating of reducing or inhibiting inflammation of tissue, comprising: administering to a subject an effective amount of a combination comprising
a CDK9 inhibitor or salt thereof and
a bromodomain-containing protein 4 (BRD4) inhibitor or a salt thereof,
wherein the combination provides a synergistic reduction in an inflammation response as compared to either the CDK9 inhibitor or salt thereof or the BRD4 inhibitor or salt thereof when administered alone.
2. The method of claim 1 , wherein the combination suppresses an inflammatory response in cells near or at the site of an injury.
3. The method of claim 2 , wherein the injury is a traumatic injury.
4. The method of claim 1 , wherein the combination suppresses an inflammatory response in a cell or tissue selected from the group consisting of cartilage, chondrocyte, joint, synovial cell, meniscal cell, ligament, and bone.
5. The method of claim 1 , wherein the inflammatory response is an acute inflammatory response.
6. The method of claim 1 , wherein the inflammatory response is activation of a catabolic pathway in a cell or tissue selected from the group consisting of cartilage, chondrocyte, joint, synovial cell, meniscal cell, ligament, and bone.
7. The method of claim 1 , further comprising reducing or inhibiting transcriptional activation of one or more primary response genes.
8. The method of claim 7 , wherein the primary response genes comprise one or more of IL-1β (interleukin-1), inducible nitric oxide synthase (iNOS), COX2 (cyclooxygenase-2), IL-6 (interleukin-6), TNF-α (tumor necrosis factor alpha), MMP-1 (matrix metalloproteinase-1), MMP-3 (matrix metalloproteinase-3), MMP-9 (matrix metalloproteinase-9), MMP-13 (matrix metalloproteinase-13), ADAMTS4 (aggrecanase).
9. The method of claim 1 , wherein the combination is administered within about 10 days of injury.
10. The method of claim 1 , wherein the combination thereof is administered within about 1 to 4 days of injury.
11. The method of claim 1 , wherein the combination is administered within about 3 hours of injury.
12. The method of claim 1 , wherein the combination reduces, delays, inhibits or prevents future onset of osteoarthritis.
13. The method of claim 1 , wherein the CDK9 inhibitor or salt thereof is flavopiridol or a salt thereof.
14. The method of claim 1 , wherein the CDK9 inhibitor or salt thereof is selected from the group consisting of:
4-(3,5-diamino-1H-pyrazol-4-ylazo)-phenol;
2-(pyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridinone; and
2-pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one (PHA-767491).
15. The method of claim 1 , wherein the inhibitor of BRD4 is selected from the group consisting of:
(S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate (JQ1, CAS Number 1268524-70-4); and
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzo-diazepin-4-yl]-N-ethylacetamide (GSK525762A, CAS Number 1260907-17-2).
16. The method of claim 1 , wherein the CDK9 inhibitor or salt thereof is flavopiridol or a salt thereof, and wherein the inhibitor of BRD4 is selected from the group consisting of JQ1 (CAS Number 1268524-70-4) and GSK525762A (CAS Number 1260907-17-2).
17. The method of claim 1 , wherein administration of the combination is repeated or sustained.
18. The method of claim 1 , wherein the administration of the combination decreases pain, decreases swelling, increases joint mobility, or any combination thereof.